Related Experiment Video

Updated: Sep 15, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease

Maxime Borgeaud1, Timothée Olivier1, Jair Bar2,3

  • 1Oncology Department, University Hospital Geneva, Geneva, Switzerland.

CA: a Cancer Journal for Clinicians
|July 17, 2025
PubMed

Insights

Targeted therapies for epidermal growth factor receptor (EGFR) mutations have transformed lung cancer treatment. Optimizing patient selection and understanding resistance are key to maximizing benefits from these advanced EGFR tyrosine kinase inhibitor (TKI) strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Activating mutations in the epidermal growth factor receptor (EGFR) gene are crucial drivers in non-small cell lung cancer (NSCLC).
  • EGFR tyrosine kinase inhibitors (TKIs) represent a paradigm shift in treating EGFR-mutant NSCLC, offering improved outcomes over traditional chemotherapy.

Purpose of the Study:

  • To provide a comprehensive review of the current treatment landscape for EGFR-mutant NSCLC.
  • To highlight recent advancements in targeted therapies, combination strategies, and biomarker-driven approaches.
  • To discuss strategies for optimizing treatment and overcoming resistance mechanisms.

Main Methods:

  • Review of recent clinical trials and scientific literature.
  • Analysis of treatment paradigms for early-stage, locally advanced, and metastatic EGFR-mutant NSCLC.
  • Exploration of emerging biomarkers and resistance mechanisms.

Main Results:

  • EGFR TKIs are increasingly integrated into various stages of NSCLC management.
  • Combination strategies show promise for improved progression-free survival but require careful toxicity and cost considerations.
  • Biomarkers and understanding resistance mechanisms are critical for refining treatment decisions and expanding therapeutic options.

Conclusions:

  • Recent advancements have significantly reshaped EGFR-mutant NSCLC treatment, with TKIs playing a central role.
  • Precise patient selection, leveraging biomarkers, and addressing resistance are essential for optimizing therapeutic benefits.
  • Continued research is vital to further refine treatment strategies and improve patient outcomes.
Keywords:
activating mutationsepidermal growth factor receptor (EGFR)non‐small cell lung cancer (NSCLC)tyrosine kinase inhibitors (TKIs)

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K